Other Projects: Production of recombinant proteins for diagnostic use
In addition to the projects related to the SARS-COV-2 pandemic, SkyBio has launched a project for the production of recombinant proteins.
Under agreement with leading public institutions, SkyBio is producing recombinant alpha-synuclein and tau proteins for use in research, in addition to RBD. However, one of these proteins, alpha -synuclein, has recently expanded its market since it is the main input for a new diagnostic method for Parkinson’s disease. A method designated RT-QuiC has been shown to be able to detect and quantify the presence of aggregated species of alpha-synuclein in cerebrospinal fluids, skin and olfactory mucosa samples. The critical input of this method is purified recombinant alpha-synuclein, a protein of high commercial value that we have been producing on an on-going basis on a laboratory scale for some years and that is currently in the process of being scaled up to another level.